Role of thalidomide in previously untreated patients with multiple myeloma

Expert Review of Anticancer Therapy

Volumn 8, Issue 10, 2008, Pages 1569-1580

  Musto, Pellegrino ^a   D'Auria, Fiorella ^a   Pietrantuono, Giuseppe ^a   Bringhen, Sara ^b   Morabito, Fortunato ^c   Di Raimondo, Francesco ^d   Pozzi, Samantha ^e   Sacchi, Stefano ^e   Boccadoro, Mario ^b   Palumbo, Antonio ^b  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c ANNUNZIATA HOSPITAL   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; First line therapy; Lenalidomide; Melphalan; Myeloma; Peripheral neuropathy; Thalidomide; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA2B INTERFERON; ANTHRACYCLINE DERIVATIVE; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIVIRUS AGENT; BORTEZOMIB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ENOXAPARIN; HEPARIN; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; METHYLPREDNISOLONE; PAMIDRONIC ACID; PLACEBO; PREDNISONE; SALICYLIC ACID DERIVATIVE; STEROID; THALIDOMIDE; VINCRISTINE; WARFARIN;

ADJUVANT THERAPY; ANTIANGIOGENIC ACTIVITY; ARTICLE; ARTIFICIAL HEART PACEMAKER; ATAXIA; AUTONOMIC NEUROPATHY; BLOOD TOXICITY; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; CONFUSION; CONSTIPATION; DEEP VEIN THROMBOSIS; DEPRESSION; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG PULSE THERAPY; DRUG RESPONSE; DRUG WITHDRAWAL; EDEMA; ELDERLY CARE; ERYTHEMA MULTIFORME; ERYTHRODERMA; FATIGUE; GOLD STANDARD; HAND FOOT SYNDROME; HEARING LOSS; HERPES ZOSTER; HUMAN; HYPERKALEMIA; HYPOTHYROIDISM; INFECTION; INTESTINE OBSTRUCTION; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; LUNG EMBOLISM; MACULOPAPULAR RASH; MALAISE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PLEIOTROPY; PULMONARY HYPERTENSION; REDUCED INTENSITY CONDITIONING; RISK FACTOR; SALVAGE THERAPY; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SINUS BRADYCARDIA; SKIN MANIFESTATION; SOMNOLENCE; SYNCOPE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TOXIC EPIDERMAL NECROLYSIS; TREMOR; WEAKNESS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DEXAMETHASONE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; MELPHALAN; MULTIPLE MYELOMA; THALIDOMIDE;

EID: 55249087667     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.10.1569     Document Type: Article

References (55)

1. Palumbo A, Facon T, Sonneveld P et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood 111, 3968-3977 (2008).
2. Kastritis E, Dimopoulos MA. Thalidomide in the treatment of multiple myeloma. Best Pract. Res. Clin. Haematol. 20, 681-699 (2007).
3. Glasmacher A, Hahn C, Hoffmann F et al. A systematic review of Phase II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br. J. Hematol. 132, 584-593 (2006).
4. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br. J. Haematol. 121, 749-757 (2003).
5. Kyle RA, Remstein ED, Therneau TM et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl. J. Med. 356, 2582-2590 (2007).
6. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J. Clin. Oncol. 21, 16-19 (2003).
7. Rajkumar SV, Gertz MA, Lacy MQ et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 17, 775-779 (2003).
8. Rajkumar SV, Hayman S, Gertz MA et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J. Clin. Oncol. 20, 3419-3423 (2002).
9. Cavo M, Zamagni E, Tosi P et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 89, 826-831 (2004).
10. Abdelkefi A, Torjman L, Ben Romdhane N et al. First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma. Bone Marrow Transplant. 36, 193-198 (2005).
11. Cavo M, Zamagni E, Tosi P et al. Superiority of thalidomide and dexamethasone over vincristine doxorubicin dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106(1), 35-39 (2005).
12. Cavo M, Terragna C, Testoni N et al. Incorporation of thalidomide into up-front double autologous stem-cell transplantation (ASCT) for newly diagnosed multiple fails to overcome the poor prognosis imparted by chromosome 13 deletion. Presented at: 13th European Hematology Association Annual Meeting. Copenhagen, Denmark, June 12-15 2008. Haematologica 93 (Suppl. 1) (2008) (Abstract 206).
13. Vogl DT, Liu SV, Chong EA et al. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support. Am. J. Hematol. 82, 1071-1075 (2007).
14. Dingli D, Rajkumar SV, Nowakowski GS et al. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a Phase II trial. Haematologica 90, 1650-1654 (2005).
15. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol. 24, 431-436 (2006).
16. Rajkumar SV, Rosiñol L, Hussein M et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J. Clin. Oncol. 26, 2171-2177 (2008).
17. Macro M, Divine M, Uzunhan Y et al. Dexamethasone+thalidomide (dex/thal) compared with VAD as a pre-transplant treatment in newly diagnosed multiple myeloma (MM): a randomized trial. Presented at: 48th American Society of Hematology Annual Meeting. FL, USA, 9-12 December 2006. Blood 108 (2006) (Abstract 57).
18. Ludwig H, Tothova E, Hajek R et al. Thalidomide-dexamethasone vs. melphalan-prednisone as first line treatment and thalidomide-interferon vs. interferon maintenance therapy in elderly patients with multiple myeloma. Presented at: 49th American Society of Hematology Annual Meeting. GA, USA, 8-11 December 2007. Blood 110, (2007) (Abstract 529).
19. Musto P, D'Auria F. Melphalan: old and new uses of a stiff master drug for multiple myeloma. Expert Opin. Invest. Drugs 25, 4459-4465 (2007).
20. Palumbo A, Bertola A, Musto P et al. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. Cancer 104, 1428-1433 (2005).
21. Palumbo A, Bringhen S, Caravita T et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367, 825-831 (2006).
22. Palumbo A, Bringhen S, Liberati AM et al. Oral melphalan, prednisone and thalidomide in elderly patients with multiple myeloma: updated results of a randomised controlled trial. Blood 25 (28), 4459-4465 (2008).
23. Facon T, Mary J, Hulin C et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced intensity antologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370, 1209-1218 (2007).
24. Hulin C, Facon T, Rodon P et al. Melphalan-prednisone-thafidomide (MP-T) demonstrates a significant survival advantage in elderly patients >75 years with multiple myelorna compared with melphalan and prednisone (MP) in a randomized, double blind, placebo-controlled trial IFM 01-01. Presented at: 49th American Society of Hematology Annual Meeting. GA, USA, 8-11 December 2007. Blood 110 (2007) (Abstract 75).
25. Gulbrandsen N, Waage A, Gimsing P et al. A randomised placebo-contolled study with melphalan/prednisone vs melphaln/ prednisone- thalidomide: quality of life and toxicity. Presented at: 13th European Hematology Association Annual Meeting. Copenhagen, Denmark, June 12-15 2008. Haematologica 93(Suppl. 1) (2008) (Abstract 209).
26. Wijermans P, Schaafsma M, Van Norden Y et al. Melphalan + prednisone vs melphaln + prednisone + thalidomide in induction therapy for multiple myeloma in elderly patients: first interim result of the Dutch cooperative group HOVON. Presented at: 13th European Hematology Association Annual Meeting. Copenhagen, Denmark, June 12-15 2008. Haematologica 93 (Suppl. 1) (2008) (Abstract 440).
27. Dimopoulos MA, Anagnostopoulos A, Terpos E et al. Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. Haematologica 91, 252-254 (2006).
28. Breitkreutz I, Lokhorst HM, Raab MS et al. Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia 21, 1294-1299 (2007).
29. Lokhorst HM, Schmidt-Wolf I, Sonneveld P et al. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica 93, 124-127 (2008).
30. Offidani M, Corvatta L, Piersantelli MN et al. Thalidomide, dexamethasone and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood 108, 2159-2164 (2006).
31. Zervas K, Dimopoulus MA, Hatzicharissi E et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a Phase II multicenter study. Ann. Oncol. 15, 134-138 (2004).
32. Hussein MA, Baz R, Srkalovic G et al. Phase II study ofpegylated liposomal doxorubicin, vincristine, decreasedfrequency dexamethasone, and thalidomide in newly diagnosed and relapsed/refractory multiple myeloma. Mayo Clin. Proc. 81, 889-895 (2006).
33. Zervas K, Mihou D, Katodritou E et al. VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek myeloma study group. Ann. Oncol. 18, 1369-1375 (2007).
34. Hassoun H, Reich L, Klimek VM et al. Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective and well tolerated initial therapy for multiple myeloma. Br. J. Haematol.
35. Wu P, Davies FE, Horton C et al. The combination of cyclophosphamide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide- vincristine-doxorubicin-methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis. Leuk. Lymphoma 47, 2335-2338 (2006).
36. Jagannath S, Bensinger B, Vescio R et al. A Phase II study of bortezomib (Velcade®), cylophosphamide (Cytoxan®), thalidomide (Thalomid®) and dexamethasone as first-line therapy for multiple myeloma. Presented at: 49th American Society of Hematology Annual Meeting. GA, USA, 8-11 December 2007. Blood 110 (2007) (Abstract 188).
37. Barlogie B, Tricot G, Anaissie E et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N. Engl. J. Med. 354, 1021-4030 (2006).
38. Zangari M, van Rhee F, Anaissie E et al. Eight-year median survival in multiple myetoma after Total Therapy 2: roles of thalidomide and consolidation chemotherapy in the context of Total Therapy 1. Br. J. Haematol. 141(4), 433-444 (2008).
39. Barlogie B, Pineda-Roman M, van Rhee F et al. Thalidomide arm of total therapy 2 improves complete remission duration and survival in myelorna patients with metaphase cytogenetic abnormalities. Blood (2008) (Epub ahead of print).
40. Cavo M, Parriarca F, Tacchetti P et al. Bortezomib (Velcade)-thatidomide-dexamethasone (VTD) vs thalidomide-dexamethasone (TD) in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM). Presented at: 49th American Society ofHematology Annual Meeting. Atlanta, USA, 8-11 December 2007. Blood 110 (2007) (Abstract 73).
41. Hicks LK, Haynes AE, Reece DE et al. A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. Cancer Treat. Rev. 34(5), 444-452 (2008).
42. Moreau P, Hulin C, Facon T. Frontline treatment of multiple myeloma in elderly patients. Blood Rev. (2008) (Epub ahead of print).
43. Palumbo A, Rajkumar SV, Dimopoulos MA et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22, 414-423 (2008).
44. Palumbo A, Cavo M, Bringhen S et al. Enoxaparin versus aspirin versus low-fixeddose of warfarin in newly diagnosed myeloma patients treated with thalidomide containing regimens: a randomized, controlled trial. Presented at: 13th European Hematology Association Annual Meeting. Copenhagen, Denmark, June 12-15 2008. Haematologica 93(Suppl. 1) (2008) (Abstract 910).
45. Mateos MV, Hernández JM, Hernández MT et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica 93, 560-565 (2008).
46. Palumbo A, Falco P, Corradini P et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA - Italian Multiple Myeloma Network. J Clin. Oncol. 25, 4459-4465 (2007).
47. Rajkumar SV, Jacobus S, Callander N et al. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. Presented at: 49th American Society of Hematology Annual Meeting. GA, USA, 8-11 December 2007. Blood 110 (2007) (Abstract 74).
48. Brinker BT, Waller EK, Leong T et al. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. Cancer 106, 2171-2180 (2006).
49. Attal M, Harousseau JL, Leyvraz S et al. Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood 108, 3289-3294 (2006).
50. Feyler S, Rawstron A, Jackson G, Snowden JA, Cocks K, Johnson RJ. Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum Phase II study. Br. J. Haematol. 139, 429-433 (2007).
51. Ladetto M, Pagliano G, Avonto I et al. Consolidation with bortezomib, thalidomide and dexamethasone induces molecular remissions in autografted multiple myeloma patients. Presented at: 49th American Society of Hematology Annual Meeting. GA, USA, 8-11 December 2007. Blood 110 (2007) (Abstract 530).
52. Abdelkefi A, Ladeb S, Torjman L et al. Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood 111, 1805-1810 (2008).
53. Barlogie B, Shaughnessy JD Jr, Crowley J. Duration of survival in patients with myeloma treated with thalidomide. N. Engl. J. Med. 359, 210-212 (2008).
54. Barlogie B, van Rhee F, Shaughnessy JD jr et al. Seven year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood (2008) (Epub ahead of print).
55. Morgan GJ, Davies FE, Owen RG et al. Thalidomide combinations improve response rates; results from the MRC IX study. Blood 110 (2007) (Abstract 3593).